By: IPP Bureau
Last updated : January 31, 2022 3:16 pm
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported a total income of Rs. 10,295.57 crore during the period ended December 31, 2021 as compared to Rs. 9848.82 crore during the period ended September 30, 2021.
The company has posted a net profit of Rs. 2058.80 crore for the period ended December 31, 2021 as against a net profit of Rs. 2047.01 crores for the period ended September 30, 2021.
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 10,295.57 crores during the period ended December 31, 2021 as compared to Rs.9151.73 crores during the period ended December 31, 2020.
The company has posted a net profit of Rs. 2058.80 crore for the period ended December 31, 2021 as against net profit of Rs.1852.48 crore for the period ended December 31, 2020.
Financial Results (nine-month ended FY2022) - YoY Comparison
The company has reported total income of Rs.30015.65 crore during the nine-month period ended December 31, 2021 as compared to Rs.25699.68 crore during the nine-month period ended December 31, 2020.
The company has posted a net profit of Rs.5549.98 crores for the nine-month period ended December 31, 2021 as against a net profit of Rs.2009.67 crore for the nine-month period ended December 31, 2020.
Dilip Shanghvi, Managing Director of the company said, “We achieved a sustained momentum and good growth across businesses; despite rising costs, we have achieved higher profitability. Our India business continues to grow faster than market, leading to increase in market share. Our global specialty business for the first nine months has already crossed previous full-year revenues. We remain steadfast in our focus on topline growth, operational efficiencies and business continuity while simultaneously continuing to expand our global specialty presence.”